In this chapter we review the concept that endocrine resistance (intrinsic and acquired) as the major obstacle in the clinic to the effective treatment of ER+ HER2/neu negative breast cancer and emphasize the need to mechanistically understand how endocrine resistance develops to SERMs, SERDs, and AIs delivered as single agents or in combination with CDKi’s. This evidence concerns the gene ESR1 and breast cancer.